ASRS Live: Apellis providing update on review of safety events with pegcetacoplan injection for GA
July 30th 2023During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.
ASRS Live: Presentations and topics at ASRS that are key for retina specialists
July 30th 2023Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.
ASRS 2023: Efficacy and safety of biosimilars ranibizumab-nuna and ranibizumab-eqrn in clinical use
July 30th 2023This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.
ASRS Live: Regeneron presents aflibercept 8 mg two-year results from PHOTON trial in DME
July 30th 2023In a presentation at the American Society of Retina Specialists 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the impact aflibercept 8 mg could have in reducing the treatment burden for patients diagnosed with DME.
ASRS Live: Results of GATHER 1 and GATHER 2 clinical trials with Carl Danzig, MD
July 29th 2023Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.
ASRS 2023: Premier meeting for retina science and innovation
July 12th 2023ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.
ASRS LIVE: TRUCKEE Study shows real-world safety and efficacy of faricimab for neovascular AMD
July 16th 2022Speaking at the American Society of Retina Specialists 2022 annual meeting in New York, Carl Danzig, MD, detailed how treatment with faricimab in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments.
ASRS LIVE: Tools developed to identify risk of vision loss to diabetic retinopathy
July 15th 2022During a presentation at the American Society of Retina Specialists 2022 annual meeting in New York, Bobeck S. Modjtahedi, MD, presented results of a study that examined the accuracy of tools for predicting the risk of vision-threatening diabetic retinopathy.
ASRS Live: Diabetic therapy metformin may have protective effect against AMD
July 15th 2022In a presentation at the American Society of Retina Specialists, Dimitra Skondra, MD, PhD, points out that the low-to-moderate doses of metformin carried the greatest potential benefit in a retrospective case-control study.
ASRS LIVE: Pearls for tackling pediatric retinal detachment surgery in US
July 14th 2022In a presentation at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Yoshihiro Yonekawa, MD, detailed that primary scleral buckling achieved the best visual acuity, and pointed out that rhegmatogenous detachments increased with age.
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD
July 14th 2022In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Novel therapy using thermogel prevents retinal scarring
July 5th 2022A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.